BioGeometry Series A extension. Beijing based BioGeometry closed a Series A extension led by China Life Capital, taking its total Series A funding above $100 million, Endpoints News reported on October 28, with Dealroom reporting the same extension and investor group. The four year old company builds generative AI models for protein and drug design, described as GeoFlow at the molecular level and GeoCell at the cellular level, paired with automated laboratories, and says several bispecific antibody programs are slated to enter clinical trials in 2027. Sources: Endpoints News and Dealroom News, October 28, 2026.
Flagship merges three startups into Etcelera. Flagship Pioneering has combined parts of three portfolio companies, Etiome, Cellarity and Empress Therapeutics, into a new company, Etcelera Therapeutics, led by former Adaptimmune chief executive Adrian Rawcliffe, BioPharma Dive reported on October 29. The three predecessor companies had raised $374 million between them, no new funding was announced, and Etcelera will work on hematological, immune and metabolic fibrotic disorders, starting with programs in myelofibrosis and essential thrombocythemia. A Cellarity discovered oral sickle cell drug will be moved into a separate standalone company. Source: BioPharma Dive, October 29, 2026.
Industry split over the China COINS rule. STAT reported on October 29 that the biopharma industry is at odds over the impact of the Treasury Department’s new China investment rules, a headline level update to this site’s October 28 story on expert warnings that complex China collaborations could be treated as banned joint ventures. No final rule text has changed in this window. Source: STAT, October 29, 2026.
Lawmaker seeks GAO probe of TrumpRx. A lawmaker has asked the Government Accountability Office to probe the TrumpRx drug pricing platform over claims about the savings it delivers, STAT reported on October 28. It is a request for an investigation, not a finding, and no GAO decision to proceed was reported in this window. Source: STAT, October 28, 2026.
Pfizer India site closure and cancer drug supply. Endpoints News reported on October 28 that a Pfizer site closure in India risks exacerbating cancer drug shortages. The item is single sourced in this run, with no company statement read, and is carried as a supply watch item rather than a confirmed shortage. Source: Endpoints News, October 28, 2026.
Biogen litifilimab questions. Analysts are pressing Biogen on its lupus drug litifilimab ahead of pivotal readouts, Endpoints News reported on October 28, following the company’s third quarter results covered in yesterday’s edition. No new trial data were released in this window. Source: Endpoints News, October 28, 2026.
MHRA Class 2 recall of Mynzepli. The UK regulator issued a Class 2 medicines recall for Advanz Pharma’s Mynzepli 40 mg per mL solution for injection in pre filled syringes, reference EL(26)A/44, on October 29. Class 2 recalls require action within 48 hours at pharmacy and wholesaler level. Source: UK MHRA, via GOV.UK, October 29, 2026.
Not repeated: Artiva’s wind down after two patient deaths (covered October 27 from the company’s SEC filing, including the 94 percent workforce cut that a Genetic Engineering News version of the same announcement restated), the Aspen Neuroscience and Bambusa IPO terms and the AstraZeneca against Takeda gastric ADC comparison (all covered October 27), the Bon Secours Mercy Health $5.7 billion Surgery Partners deal (covered October 25 and updated October 27), Lilly’s retatrutide diabetes result, GSK’s quarter, the FDA individualized gene editing guidance and the HHS peptide compounding decision (all covered October 28).